Multispecific antibodies, multispecific activatable antibodies and methods of using the same
Номер патента: NZ755670A
Опубликовано: 25-03-2022
Автор(ы): Bryan Allen Irving, Chihunt Wong, Daniel Robert Hostetter, Henry Bernard Lowman, James William West, Porte Sherry Lynn La
Принадлежит: Cytomx Therapeutics Inc
Опубликовано: 25-03-2022
Автор(ы): Bryan Allen Irving, Chihunt Wong, Daniel Robert Hostetter, Henry Bernard Lowman, James William West, Porte Sherry Lynn La
Принадлежит: Cytomx Therapeutics Inc
Реферат: The invention relates to a bispecific activatable antibody comprising (i) a first arm comprising an antigen-binding fragment of an immune effector cell engaging antibody that includes a first antibody or antigen-binding fragment thereof (AB1) that binds a first target, wherein the first target is an immune effector cell target; (ii) a second arm comprising an antigen-binding fragment of a target binding antibody that includes a second antibody or antigen-binding fragment thereof (AB2) that binds a second target; wherein the AB1 is attached to a first masking moiety (MM1) such that coupling of the MM1 to the AB1 reduces the ability of the AB1 to bind the first target; wherein the MM1 is coupled to the AB1 via a first cleavable moiety (CM1) sequence that includes a substrate for a protease; wherein the first arm of the bispecific activatable antibody in an uncleaved state has a structural arrangement from N-terminus to C-terminus as follows: MM1-CM1-AB1, wherein the structural arrangement optionally comprises a linkage peptide between MM1 and CM1 and optionally comprises a linkage peptide between CM1 and AB1; wherein the AB2 is attached to a second masking moiety (MM2) such that coupling of the MM2 to the AB2 reduces the ability of the AB2 to bind the second target; wherein the MM2 is coupled to the AB2 via a second cleavable moiety (CM2) sequence that includes a substrate for a protease; and wherein the second arm of the bispecific activatable antibody in an uncleaved state has a structural arrangement from N-terminus to C-terminus as follows: MM2-CM2-AB2, wherein the structural arrangement optionally comprises a linkage peptide between MM2 and CM2 and optionally comprises a linkage peptide between CM2 and AB2.
Compositions that target cd138 and cd3 and methods of making and using the same
Номер патента: WO2024138144A1. Автор: Jeffrey A. Medin,Charles E. HAY. Владелец: THE MEDICAL COLLEGE OF WISCONSIN, INC.. Дата публикации: 2024-06-27.